LIFECORE BIOMEDICAL, INC. (LFCR)

Import this data to Google Sheets with:

=jivedata("LFCR","financials")

Full statements spill as a table. For one cell: =jivedata("LFCR","Revenue") or =jivedata("LFCR","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

LIFECORE BIOMEDICAL, INC.

LFCR • CIK 0001005286

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Including Assessed Tax	$103,269	$128,261	$128,867	$114,629
Cost of Goods and Services Sold	$75,284	$86,411	$88,569	$81,621
Gross Profit	$27,985	$41,850	$40,298	$33,008
Research and Development Expense	$8,736	$8,575	$8,258	$6,864
Selling, General and Administrative Expense	$38,969	$40,463	$44,046	$40,861
Restructuring Charges	$4,184	$1,207	$-1,747	$887
Operating Income (Loss)	$-21,796	$-8,844	$-17,245	$-15,648
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	—	$39,500	$409	$-2,258
Other Nonoperating Income (Expense)	$-1,159	$-3,052	$-3	$-287
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-63,928	$9,514	$-38,674	$-43,853
Income Tax Expense (Benefit)	$308	$183	$43	$84
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent	—	—	$-38,717	$-38,717
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	—	—	$0	$0
Net Income (Loss) Attributable to Parent	$-99,563	$12,013	$-38,717	$-43,937
Preferred Stock Dividends, Income Statement Impact	—	—	$3,318	$3,460
Temporary Equity, Accretion to Redemption Value, Adjustment	—	—	$192	$190
PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	—	—	$2,132	$2,132
Net Income (Loss) Available to Common Stockholders, Basic	—	—	$-44,359	$-49,719
Weighted Average Number of Shares Outstanding, Basic	29,958,000	30,474,000	34,818,906	35,330,932
Weighted Average Number of Shares Outstanding, Diluted	29,958,000	36,658,000	34,818,906	35,330,932
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock	—	5,847,000	0	0
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	—	337,000	0	0

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Property, Plant and Equipment, Net	$134,390	$148,598	$129,006	$123,714
Goodwill	$13,881	$13,881	$13,881	$13,881
Intangible Assets, Net (Excluding Goodwill)	—	$4,200	$4,200	$4,200
Other Assets, Noncurrent	$2,917	$3,806	$6,578	$8,214
Assets	$253,545	$253,960	$239,342	$229,500
Long-term Debt, Excluding Current Maturities	$84,256	$100,819	—	$110,528
Derivative Liability, Noncurrent	$64,900	$25,400	$24,991	$30,922
Other Liabilities, Noncurrent	$3,114	$5,086	$9,741	$6,746
Liabilities	$218,457	$200,058	$191,909	$213,407
Temporary Equity, Carrying Amount, Attributable to Parent	$39,318	$42,587	$46,097	$50,187
Cash and Cash Equivalents, at Carrying Value	$19,091	$8,462	$8,265	$17,241
Accounts Receivable, after Allowance for Credit Loss, Current	$29,024	$31,153	—	$30,303
Financing Receivable, after Allowance for Credit Loss, Current	—	—	$8,000	$0
Contract with Customer, Asset, after Allowance for Credit Loss, Current	—	—	$6,979	$7,568
Inventory, Net	$40,841	$39,979	$32,291	$25,475
Prepaid Expense and Other Assets, Current	$4,919	$1,439	$1,454	$2,952
Assets, Current	$93,875	$81,033	$85,677	$83,691
Accounts Payable, Current	$22,097	$16,334	$8,220	$7,534
Accrued Liabilities, Current	—	—	$21,958	$14,107
Liabilities, Current	$39,289	$38,872	$30,178	$21,641
Common Stock, Value, Issued	$30	$30	$37	$38
Additional Paid in Capital	$174,276	$177,808	$206,539	$210,205
Retained Earnings (Accumulated Deficit)	$-178,536	$-166,523	$-205,240	$-244,337
Stockholders' Equity Attributable to Parent	$-4,230	$11,315	$1,336	$-34,094
Accounts Receivable, Allowance for Credit Loss, Current	—	$711	$1,351	$804
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$57,006	$50,334	$57,412	$63,134
Finite-Lived Intangible Assets, Accumulated Amortization	$3,700	$3,700	$3,700	$3,700
Temporary Equity, Shares Authorized	2,000,000	2,000,000	2,000,000	2,000,000
Temporary Equity, Shares Issued	39,000	42,000	45,736	49,263
Temporary Equity, Liquidation Preference	—	—	$46,308	$50,187
Common Stock, Shares Authorized	50,000,000	50,000,000	75,000,000	75,000,000
Common Stock, Shares, Issued	30,322,000	30,563,000	37,026,234	37,697,012

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-99,563	$12,013	$-38,717	$-43,937
Net Cash Provided by (Used in) Operating Activities	$-17,441	$-217	$-206	$-4,243
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$17,448	$-10,629	$-197	$765
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$19,091	$8,462	$8,265	$23,645
Depreciation, Depletion and Amortization	$13,285	$8,859	$8,027	$8,015
Payments to Acquire Property, Plant, and Equipment	—	—	$13,415	$7,493
Share-based Payment Arrangement, Noncash Expense	$3,612	$6,201	$10,158	$9,574
Proceeds from Sale of Property, Plant, and Equipment	$0	$0	$7,000	$0
Paid-in-Kind Interest	—	—	$20,247	$23,582
Net Cash Provided by (Used in) Investing Activities	$-4,811	$-17,921	$-6,415	$-7,493
Unrealized Gain (Loss) on Derivatives	—	$39,500	$409	$-2,258
Gain (Loss) on Disposition of Other Assets	—	—	$-7,776	$-49
Gain (Loss) on Termination of Lease	—	—	$2,642	$2,642
Other Noncash Income (Expense)	$-86	$0	$-49	$350
Increase (Decrease) in Receivables	$-10,824	—	$2,262	$1,455
Proceeds from Issuance of Common Stock	$4,822	$0	$23,850	$23,849
Increase (Decrease) in Contract with Customer, Asset	—	—	$2,910	$1,542
Repayments of Long-term Lines of Credit	—	—	$145,758	$143,665
Increase (Decrease) in Inventories	$14,811	$-862	$-7,688	$-4,375
Proceeds from Long-term Lines of Credit	—	—	$128,567	$132,474
Increase (Decrease) in Other Operating Assets	—	$-2,380	$-378	$1,984
Repayments of Other Debt	—	$579	$930	$969
Increase (Decrease) in Accounts Payable	$16,038	$-6,676	$-1,670	$2,579
Payments of Debt Issuance Costs	$6,050	$231	$435	$435
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	—	—	$-5,919	$-6,254
Proceeds from Stock Options Exercised	—	$724	$0	$0
Payment, Tax Withholding, Share-based Payment Arrangement	$274	$152	$1,270	$1,587
Net Cash Provided by (Used in) Financing Activities	$39,700	$7,509	$6,424	$12,501

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("LFCR","financials")

Full statements spill as a table. For one cell: =jivedata("LFCR","Revenue") or =jivedata("LFCR","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.